SPY326.54-3.44 -1.04%
DIA265.06-1.53 -0.57%
IXIC10,911.59-274.00 -2.45%

STERIS To Acquire Key Surgical For ~$850M

Consumable product portfolio a natural extension for STERIS's Customers in sterile processing departments, operating rooms and endoscopy Compelling financial benefits - accretive to top-line growth, margins and

· 10/06/2020 07:17
  • Consumable product portfolio a natural extension for STERIS's Customers in sterile processing departments, operating rooms and endoscopy
  • Compelling financial benefits - accretive to top-line growth, margins and earnings
  • Expected to close by December 31, 2020
  • Conference call with STERIS Management today at 10:00 a.m. ET

DUBLIN, IRELAND, Oct. 06, 2020 (GLOBE NEWSWIRE) -- STERIS plc (NYSE:STE) ("STERIS" or the "Company") today announced that the Company has signed a definitive agreement to purchase Key Surgical, a portfolio company of Water Street Healthcare Partners, LLC, through a U.S. subsidiary for $850 million.  STERIS anticipates that the acquisition will qualify for a tax benefit related to tax deductible goodwill.  Adjusting for the present value of the anticipated tax benefit, the purchase price is effectively reduced to approximately $810 million.  Key Surgical, founded in 1988, is a leading global provider of consumable products serving hospitals and surgical facilities.  Annual revenue for Key Surgical in calendar 2020 is anticipated to be approximately $170 million, with adjusted EBIT of approximately $50 million.

"Key Surgical strengthens, complements and expands STERIS's product offering and reach around the globe. Their focus on the sterile processing department, operating room and endoscopy fits perfectly with our core Healthcare Customers," said Walt Rosebrough, President and Chief Executive Officer of STERIS.  "The business has demonstrated an ability to grow at rates above industry levels with its product portfolio breadth, a steady stream of new products and a highly effective commercial model.  We welcome the Key Surgical people to the STERIS team, and we look forward to working together to enhance our service to our Customers and the value for our shareholders."

Under the terms of the agreement, STERIS will purchase the shares of Key Surgical at closing.  The transaction will be financed through a combination of debt and cash on hand and is anticipated to close by December 31, 2020 pending customary closing conditions and regulatory approval.  The transaction is expected to be immediately accretive to STERIS's adjusted earnings after close and add approximately $40 million to revenue and about $0.10 to adjusted earnings per diluted share in STERIS's fiscal 2021 fourth quarter.  STERIS expects to realize annualized pre-tax earnings synergies of $10-$15 million by year three following the close.